Delivery Order SPE2DB22D9367-SPE2DB24FSW09
Award Date 2/5/24
Potential Completion Date 2/27/24
Potential Value $120K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $120,327.60 contract is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring pharmaceutical needs of military health facilities. The award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $120,327.60 contract is for the supply of Keytruda 100 mg/4 ml vials to support the medical needs of Department of Defense (DoD) healthcare facilities. This delivery order is part of a larger indefinite delivery contract (IDC) with a ceiling value of up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $160,571.40 contract is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which...
- This is a $240,857.10 firm fixed-price delivery order contract awarded by the Defense Logistics Agency Troop Support Medical to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Keytruda 100 mg/4 ml vials. The delivery order is placed under DMS Pharmaceutical Group's existing prime vendor contract, SPE2DB, with the Defense Logistics Agency valued at up to $4,999,999 through 2025. This indefinite delivery vehicle enables the DLA to issue firm fixed-price delivery...
- This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) Medical Supply Chain division. The $80,285.70 contract is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring pharmaceutical needs of military health facilities. This order is placed under DMS Pharmaceutical Group's $499,999,999 indefinite delivery contract with the DLA, which allows the agency to issue delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,142.85 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vial. The contract has an ultimate completion date of July 3, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $122,843.40 contract is for the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The award, valued at $77,505.20, is for the procurement of Keytruda 100 mg/4 ml vial (4 ml) to support the medical supply needs of military healthcare facilities. This delivery order is issued under a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, which enables the...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide KEYTRUDA 100 MG/4 ML VIAL 4ML. The order has a potential value of $80,285.70 and a completion date of February 8, 2024. DMS Pharmaceutical Group Inc. holds an indefinite delivery contract with DLA to supply a variety of pharmaceutical and medical products to support military treatment facilities globally. This specific order is delivered under...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $82,041.50 and covers the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a larger single-award Indefinite Delivery Contract...
- SPE2DB22D9367Indefinite Delivery Contract
- SPE2DB22D9367-SPE2DB24FSW09Delivery Order
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The $120,428.55 contract is for the delivery of Keytruda 100 mg/4 ml vials to fulfill the recurring pharmaceutical needs of military health facilities supported by DLA. The order is placed against DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 with DLA, valued up to $4,999,999 through 2025. This larger vehicle, known as the SPE2DB program, enables DLA to issue delivery orders for a broad range of pharmaceutical products directly to DMS Pharmaceutical Group. The contract has no set-aside designation.
Generated 5/6/24, 9:08 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $120.4k | 2/5/24 |